Regeneron Pharmaceuticals Stock Earnings Reports

Regeneron reported a strong start to 2026 with double-digit commercial and earnings growth. Total revenues rose 19% year-over-year and non-GAAP EPS grew 15%. DUPIXENT remains the company’s engine (31% constant-currency growth, ~$4.9B Q1 sales) with continued label expansions and lifecycle efforts. EYLEA HD showed rapid U.S. adoption (52% growth to $468M) while Bayer-region sales also contributed; a pending FDA decision this quarter on prefilled-syringe manufacturing could further support uptake. Libtayo grew 54% globally, aided by new adjuvant CSCC uptake. Key pipeline milestones include FDA approval of Otarmeni (for which Regeneron will provide the product for free), positive Phase III data for cemdisiran in generalized myasthenia gravis (BLA submission with an expected FDA decision in Q4), priority-review acceptance for garetosmab with an August PDUFA, ongoing complement and ophthalmology programs, advancing bispecifics and oncology assets (including fianlimab/Libtayo and multiple myeloma programs), and progress on obesity candidate olatorepatide. Financially, collaboration revenue with Sanofi grew materially and the Sanofi development balance is expected to be repaid by end of Q2, after which Regeneron’s share of collaboration profits will step up. The Board authorized a new $3 billion share repurchase program; the company generated $848M free cash flow in Q1 and ended with net cash of $15.8B. A temporary manufacturing interruption in Limerick negatively impacted GAAP gross margins and will weigh on Q2 GAAP margin, but product supply was not disrupted. Management emphasized continued R&D investment and disciplined capital allocation while pursuing strategic collaborations and the recently announced U.S. pricing agreement intended to lower patient costs while preserving innovation.